1. Introduction {#sec1}
===============

Cancer, also known as malignant tumors, can destroy the structure and function of tissues and organs and cause necrotic hemorrhage and infection, and patients may eventually die due to organ failure. In recent years, the incidence of malignant tumors has increased. In the European Union, it is estimated that there are about 1.4 million new cancer cases in a year, including 1.2 million women, and about 70,000 men and 55,000 women die of cancer \[[@B1]\]. In the United States, cancer morbidity and mortality will continue to rise, and lung cancer is expected to remain the number one cancer killer \[[@B2]\].

As one of the world\'s five most intractable diseases, cancer is an incurable disease. If it is not detected and treated in time, it can also be transferred to all parts of the body for growth and reproduction and finally lead to body weight loss, weakness, anemia, loss of appetite fever, damage of viscera function, etc. \[[@B3]\]. The current cancer treatment is mainly surgery, chemotherapy, and radiotherapy, but both of these treatments cannot reduce the recurrence and metastasis after surgery. It is necessary to cooperate with other treatments after the operation \[[@B4]\]. The effects of radiotherapy and chemotherapy are obvious, but the obvious disadvantage is side effects. Cancer patients will be weak because of illness, and their constitution will be worse after chemotherapy and chemotherapy, which will lead to a decline in the quality of life and even make the body weaker and unable to withstand the next treatment \[[@B5]\].

Traditional Chinese medicine (TCM) treatment is a traditional treatment method in China. For cancer, combination of traditional Chinese medicine can promote the rehabilitation of patients and prevent postoperative tumor recurrence and metastasis. At the same time, traditional Chinese medicine can reduce side effects by radiotherapy and chemotherapy and improve the quality of life (QOL) of patients and even improve the survival rate \[[@B6], [@B7]\]. The Radix Salviae Miltiorrhizae (Danshen) originated from "Shen Nong\'s Herbal Classic" is a well-known TCM herb (China Pharmacopoeia Committee, 2005), and it has been used in clinical practice for over 2000 years. However, there was no consensus on the role of Danshen formulae in cancer treatment \[[@B8]--[@B20]\]. To scientifically validate the efficacy and safety of the Danshen formulae, the meta-analysis evaluated the value of Danshen formulae for the treatment of cancer based on high quality randomized controlled trials (RCTs).

2. Methods {#sec2}
==========

This systematic review and meta-analysis are based on the Preferred Reporting Items for Systematic Reviews and Meta Analyses: PRISMA statement search strategy \[[@B21]\].

2.1. Search Strategy {#sec2.1}
--------------------

We conducted literature retrieval through 5 database systems including PubMed, the Cochrane Library, EMBASE, and the China National Knowledge Infrastructure (CNKI), VIP database, Wanfang database. The retrieval deadline was September 2018. The main search terms of this paper included the following three parts: (Traditional Chinese Medicine OR Traditional Medicine, Chinese OR TCM OR Zhong Yi Xue OR Chinese Traditional Medicine OR Chinese Medicine, Traditional OR herbal medicine OR Medicine, Chinese Traditional) AND (Neoplasia OR Neoplasias OR Neoplasm OR Tumors OR Tumor OR Cancer OR Malignant Neoplasms OR Malignant Neoplasm OR Neoplasm, Malignant OR Neoplasms, Malignant OR Malignancy OR Malignancies OR Neoplasms). There was no restriction on the type of language. In addition, we used manual references to previously published system reviews to manually search for additional related research. The specific herb name "Danshen" has not been specifically searched to ensure that as many herbal formulae as possible were included.

2.2. Inclusion Criteria {#sec2.2}
-----------------------

\(1\) Type of participants: researches involving patients with any type of cancer

\(2\) Type of study: only RCTs that assessed the efficacy and safety of cancer treatment were eligible

\(3\) Type of intervention: Danshen must be included in the herbal formula used in the experimental group. There were no restrictions on the form of the drug (e.g., decoction, injection, pill, and capsule), dosage, frequency, or treatment time. Control group medications include placebo or conventional medication

\(4\) Types of results: the efficacy of cancer treatment was evaluated through OS (overall survival), duration of overall response, duration of stable disease, DFS (disease-free survival), PFS (progression-free survival), TTP (time to progression), TTF (time to failure), DCR (disease control rate), ORR (overall response rate), RR (response rate), CBR (clinical benefit rate), and ORR (objective response rate). Secondary outcome measures were quality of life (QOL) or side effects (such as fatigue, pain, infection/fever, anemia, diarrhea, nausea and vomiting, hair loss, and myelosuppression)

\(5\) RoB scored≥4 points

2.3. Exclusion Criteria {#sec2.3}
-----------------------

If the above conditions were not met, the study was excluded. In addition, the following documents were also excluded: (1) duplicate publications and (2) case series, review, animal studies, and pharmacological experiments, (3) other TCM therapies, such as acupuncture, massage, qigong, moxibustion, and Taiji were included in the study.

2.4. Study Selection {#sec2.4}
--------------------

The two reviewers selected the study by screening the title and summary of the selected qualifying RCTs independently. Obtain and read the full text of studies that may meet predefined criteria. When the data were duplicated, only the most recent information is selected. The differences in the study choices were resolved by discussion with the latter corresponding author.

2.5. Quality Assessment {#sec2.5}
-----------------------

The methodological quality of the included studies was assessed using the risk of bias (RoB) tools, according to Cochran\'s Systematic Review Handbook on interventions \[[@B22]\]. Including the following seven contents: (A) random sequence generation (selection bias); (B) allocation concealment (selection bias); (C) blinding of participants and personnel (performance bias); (D) blinding of outcome assessment (detection bias); (E) incomplete outcome data (attrition bias); (F) selective reporting (reporting bias); (G) other bias.

2.6. Data Extraction {#sec2.6}
--------------------

Two reviewers used predesigned standard data extraction forms to independently extract data from eligible trials. The excerpts were as follows: (1) the year of publication and the name of the first author, the language of publication, the type of cancer; (2) the characteristics of the participants, including the number, gender, age; (3) treatment information, including intervention management details, treatment process, and side effects; (4) measurement of results.

2.7. Danshen Formulae Composition {#sec2.7}
---------------------------------

In each study, components of Danshen formula were documented, with a frequency analysis of the types of cancer it treated and common drugs combined with it.

2.8. Data Analysis {#sec2.8}
------------------

Dates from eligible researches were aggregated and a quantitative summary was generated by Review Manager 5.3. Egger\'s test was carried out by Stata 12.0.

2.9. Effect Size {#sec2.9}
----------------

Dichotomous data were reported as odds ratio (OR) with 95% confidence intervals (CI). The OR was deliberate significant at the*P*\< 0.05 level when value 1 was not taken into the 95% CI. The purpose of this article is to explore the effectiveness of the Danshen formulae; therefore, we take the number of positive events as weights.

2.10. Heterogeneity {#sec2.10}
-------------------

The statistical heterogeneity of the trials was assessed using Cochran*Q* tests and *I*^2^ statistics. If there is no absence of heterogeneity or moderate heterogeneity (*P* \> 0.1, *I*^2^ \< 50%) \[[@B23]\], a fixed effect model (FEM) will be used; otherwise, a random effects model (REM) will be applied.

2.11. Publication Bias {#sec2.11}
----------------------

If a research project contained more than 10 studies, the funnel plot were used to test publication bias.

2.12. Sensitivity Analysis {#sec2.12}
--------------------------

Sensitivity analysis was performed to test the effect of a single study on the combined effect by removing the individual survey. If the estimated value of the point after deleting a study fell beyond the 95% CI of the total effect amount (or was significantly different from the combined effect amount), we considered the study in question to have exerted a great influence on the combined effect amount and that this study required further review.

3. Results {#sec3}
==========

3.1. Description of Studies {#sec3.1}
---------------------------

A total of 3209 studies were searched by 4 electronic databases and other sources, and 2664 records were retained after deduplication. Of these, 366 studies were unrelated to cancer, 434 were animal experiments, 462 were mechanical experiments, and 728 were reviews, protocols, experiences, or case reports. By reading the full text, 762 studies, including 103 control interventions were inappropriate, lacking 50 of the control group and 70 items without full text, 200 items were not really RCTs, 99 items did not use the Danshen formula, and 142 included other CAM treatments, such as Acupuncture, Qigong, and 90 methodology that is of low quality. In the end, the study included 13 studies with 1045 patients that met the Cochrane Robb score of 4 and conducted a meta-analysis. A PRISMA flowed graph describe the search process and research options ([Figure 1](#fig1){ref-type="fig"}).

3.2. Basic Characters of the Included Studies {#sec3.2}
---------------------------------------------

The characteristics of the 13 studies included the contents summarized in [Table 1](#tab1){ref-type="table"}. All the eligible studies were conducted in China, with four articles published in English \[[@B9]--[@B11], [@B13]\] and the rest in Chinese \[[@B8], [@B12], [@B14]--[@B20]\]) ([Table 1](#tab1){ref-type="table"}). In this study, there are 6 related lung cancers \[[@B9]--[@B11], [@B14], [@B19], [@B20]\], 3 related to Leukemia \[[@B12], [@B17], [@B18]\], 3 related to Liver cancer \[[@B8], [@B15], [@B19]\], one related to breast or colon cancer \[[@B13]\], and one related to gastric cancer \[[@B17]\] ([Table 2](#tab2){ref-type="table"}). Because leukemia is a kind of malignant clonal disease of hematopoietic stem cells and belongs to the category of cancer, this study also included the research of leukemia. There were 10 RCTs with Overall response rate (RR) \[[@B8], [@B10]--[@B12], [@B14]--[@B19]\], 8 RCTs of them showed that Danshen formulae improved RR \[[@B10]--[@B14]\], and 2 RCTs suggested that Danshen formulae did not significantly improve RR \[[@B8], [@B11]\]. In 5 RCTs with survival rates, 4 RCTs of them indicated that Danshen Formulae improved survival rates \[[@B9], [@B15], [@B18], [@B20]\] and 1 RCT indicated that Danshen formulae did not significantly improve RR \[[@B8]\]. Seven RCTs were with side effects \[[@B10], [@B12]--[@B15], [@B17], [@B20]\] ([Table 1](#tab1){ref-type="table"}). And the results showed 605 male patients and 440 female patients included in this study ([Table 2](#tab2){ref-type="table"}). Among the 13 RCTs, 3 different Danshen formulae dosage forms were mentioned, 1 was a granule \[[@B17]\], 1 was a tablet \[[@B14]\], and the rest were decoction \[[@B8]--[@B13], [@B15], [@B16], [@B18]--[@B20]\]. In 8 Danshen formulae, Danshen plays a major role \[[@B8], [@B9], [@B12], [@B14]--[@B16], [@B19], [@B20]\] and improves the survival rate of patients; in 3 Danshen formulae, Danshen plays play an auxiliary role \[[@B10], [@B17], [@B18]\] and, in 2 RCTs, the real effect is that of other medicinal materials \[[@B11], [@B13]\]. It should be noted that one study did not involve radiotherapy, chemotherapy, or surgical treatment \[[@B19]\], while the rest were combined Chinese and western medicine ([Table 3](#tab3){ref-type="table"}).

3.3. Description of the Danshen Formulae {#sec3.3}
----------------------------------------

[Table 2](#tab2){ref-type="table"} details the components of the Danshen formulae in each study. 83 kinds of herbs were used in 13 different Danshen formulae and three dosage forms were mentioned, namely, decoction (n=11), tablets (n=1), and formula particles (n=1) ([Table 3](#tab3){ref-type="table"}). The 9 most commonly used herbs were Radix Salviae Miltiorrhizae (frequency=13), Astragalus mongholicus bunge (frequency=8), Rhizoma atractylodis Macrocephalae (frequency=5), Curcuma zedoaria (frequency=4), Agkistrodon seu bungarus (frequency=4), Poria (frequency=4), Adenophora stricta (frequency=3), Glycyrrhiza uralensis (frequency=3), and Portulaca grandiflora hook (frequency=3) ([Table 4](#tab4){ref-type="table"}).

3.4. RoB Assessment {#sec3.4}
-------------------

The RoB evaluation is shown in [Table 4](#tab4){ref-type="table"}. All studies are described as random. Twelve RCTs mentioned random allocation methods, including random sampling, picking method, hospitalization time, completely randomized digital table, and stratified permuted block method, and the rest of the study had only the words "randomized grouping". 1 RCT explicitly proposed that the study was conducted by a single blind method \[[@B9]\], 2 RCT explicitly proposed the use of double-blind method in the title or abstract \[[@B10], [@B13]\], and the rest of the studies were relatively vague about the blind method, and we need to get relevant information by reading the full text. As shown in the table, among the 13 studies, 3 articles scored 5 points \[[@B9], [@B10], [@B13]\], and the rest were scored 4 points \[[@B8], [@B11], [@B12], [@B14]--[@B20]\] ([Table 5](#tab5){ref-type="table"}).

3.5. Effectiveness {#sec3.5}
------------------

### 3.5.1. Cancer Patients Treated with Additional Danshen Formulae Have a Significantly High RR {#sec3.5.1}

Ten studies \[[@B8], [@B10]--[@B12], [@B14]--[@B19]\] analyzed RR, indicating the RR of the experimental group was higher than that of the control group (OR 2.38, 95% CI 1.66-3.42) ([Figure 2](#fig2){ref-type="fig"}). Heterogeneity test*P* = 0.21,*I*^*2*^ = 25% showed 13 included articles with no heterogeneity, so the statistical analysis with fixed effects model. Pooled OR with 95% CIs showed*Z* = 4.71,*P*\<0.00001 ([Figure 2](#fig2){ref-type="fig"}), suggesting that the difference was statistically significant. It can be considered that the RR of Danshen formulae with the general treatment regimen was higher to the control scheme without the Danshen formulae.

### 3.5.2. 1-Year Survival Rate {#sec3.5.2}

The total clinical efficacy rate 1-year survival rate between experimental group and control group was reported in 7 studies \[[@B8], [@B9], [@B11], [@B15], [@B18]--[@B20]\]. Compared with the control group, the 1-year survival rate was significantly improved after adding Danshen formulae (OR 1.70 95% CI 1.22-2.36,*Z* = 3.13,*P=*0.002), and there was a low heterogeneity (*P* = 0.27,*I*^*2*^ = 21%) ([Figure 3](#fig3){ref-type="fig"}).

### 3.5.3. 3-Year Survival Rate {#sec3.5.3}

Four researches \[[@B9], [@B11], [@B18], [@B20]\] focused on 3-year survival rate between two groups. Pooled data showed that Danshen formulae were significantly better at increasing patient\'s 3-year survival (OR 2.78, 95% CI 1.62-4.78,*Z* = 3.70,*P=*0.0002) with no heterogeneity (*P* = 0.66,*I*^*2*^ = 0%) ([Figure 4](#fig4){ref-type="fig"}).

### 3.5.4. 5-Year Survival Rate {#sec3.5.4}

Three studies recorded 5-year survival rates \[[@B9], [@B11], [@B18]\]. Pooled data indicated that experimental group had a higher 5-year survival rate (OR 8.45, 95% CI 2.53-28.27,*Z* = 3.74,*P* = 0.0005) than control group with no heterogeneity (*P* = 0.76,*I*^*2*^ = 0%) ([Figure 5](#fig5){ref-type="fig"}).

3.6. Publication Bias {#sec3.6}
---------------------

The funnel plot and further Egger\'s test were used to evaluate publication bias for RR of two groups of cancer patients. As the two results, though, showed a left-right asymmetry, but both*P*\>0.05, suggesting that there was no publication bias (Figures [6](#fig6){ref-type="fig"} and [7](#fig7){ref-type="fig"}).

3.7. Sensitivity Analysis {#sec3.7}
-------------------------

Our sensitivity analysis did not indicate that the results of any individual study would change the final outcome, indicating that none of the studies significantly affected the pooled OR and 95% CI.

3.8. Subgroup Analysis {#sec3.8}
----------------------

To evaluate the effect of Danshen formulae for different cancers, we did a subgroup analysis. Danshen formulae did not show obvious beneficial effects in gastric cancer (OR 0.90 95% CI 0.06-12.58) and lung cancer (OR 1.81 95% CI 0.98-3.36), while it was good for treatment of leukemia (OR 4.63 95% CI 2.11-10.17) and liver cancer (OR 2.15 95% CI 1.21-3.80). Pooled data indicated that Danshen formulae had beneficial effects during the treatment progress in different cancers (OR 2.38 95% CI 1.66-3.42) ([Figure 8](#fig8){ref-type="fig"}).

4. Discussion {#sec4}
=============

4.1. Summary of Evidence {#sec4.1}
------------------------

In the past decades, much work has been reported in Chinese Herbal Medicine (HCM) in the treatment of cancer \[[@B8]--[@B20], [@B24], [@B25]\], and Zhang\'s review provided evidence for the effectiveness of Danshen in the treatment of cancer \[[@B26]\]. However, there has not been a meta-analysis to study the value of Danshen formulae in cancer treatment. This paper was a systematic review of 13 high-quality RCTs, including 1045 participants, to determine the efficacy and safety of the Danshen formulae for cancer treatment. Our study showed that the Danshen formulae provide statistically significant benefits in improving RR (OR 2.38 95% CI 1.66-3.42), 1-year survival (OR 1.70 95% CI 1.22-2.36), 3-year survival (OR 2.78, 95% CI 1.62-4.78), and 5-year survival rate (OR 8.45, 95% CI 2.53-28.27). Current evidence suggests that Danshen formulae can be used as an effective adjuvant for treat cancer.

4.2. Implications for Practice {#sec4.2}
------------------------------

Modern pharmacological studies were performed on more than 10 tanshinone monomers, including tanshinone I (TNI), tanshinone A (TNIIA), tanshinone B, and cryptotanshinone (CPT), from Danshen root. Tanshinone TNI are the main bioactive components, TNIIA, and implicit tanshinone (CPT); TNIIA activity in salvia miltiorrhiza is the strongest diterpene quinine pigment; TNI and CPT are effective cytotoxic agent and can induce apoptosis and the stagnation of the cell cycle; potential mechanisms involved include raised to promote apoptosis proteins such as p53, Bax, and p21 and inhibit antiapoptotic proteins, including the Bcl-2, survivin, and c-Myc and activated caspase protein to trigger apoptosis, by activating AMP activated protein kinase and extracellular signal regulating kinase (ERK) and suppress the target of pakamycin and 70 kDa ribosomal protein S6 kinase signaling pathways; TNIIA induces autophagic cell death in various cancer cells. Furthermore, TNIIA and TNI can inhibit the migration, invasion, and metastasis of cancer cells by changing the tissue inhibitors of matrix metalloproteinase and/or metalloproteinase \[[@B26], [@B27]\]. In addition, TNIIA can also promote the differentiation of several cancer cell types and regulate the CCAAT/enhancer binding protein (C/EBP)*β* and C/EBP homologous protein. Besides, in animal models, the side effects of TNIIA, TNI, and CPT were minimal \[[@B28]\].

In addition, Danshen root also has anti-inflammatory effects. TNIIA inhibits the NF-kB induced kinase/IkappaB alpha kinase (NIK/IKKalpha), while ERK1 suppress NF-*κ*B induced by LPS and c-Jun n-terminal kinase (JNK) pathway. The anti-inflammatory effects of TNIIA may be related to the inhibition of the Toll-like receptor (TLR) signaling pathway by TNF receptor-associated factor (TRAF) 2/3/6. TNI significantly inhibits the activity of IIA secreting phospholipase A2 (GIIA), thereby blocking the formation of prostaglandin E2 (PGE~2~) in LPS-activated macrophages \[[@B27], [@B29]\]. TNI and CPT also significantly inhibit IL-12 production in LPS-activated macrophages and interferon-*γ* production in lymphocytes. Recent studies have shown that Salvia miltiorrhiza extract inhibits the production of iNOS and COX-2 by regulating NF-*κ*B and MAPKs, thereby inhibiting the secretion of inflammatory cytokines. In LPS induced RAW264.7 macrophages, salvia miltiorrhiza extract reduced the secretion of nitric oxide (NO), tumor necrosis factor- (TNF-) *α*, and interleukin 6 (IL-6) and decreased the expression of inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), and NF-*κ*B. Moreover, salvia miltiorrhiza extract can significantly inhibit the activation of JNK1/2 and ERK1/2 induced by LPS and disrupt the TLR4 dimerization in LPS-induced RAW264.7 macrophages \[[@B29]\]. Therefore, the anti-inflammatory effect of Danshen root is partly due to the blocking of TLR4 dimerization, which can be used in clinical treatment of liver injury and infection during the anticancer strategies.

Therefore, Chinese medicine practitioners usually use traditional Chinese medicines similar to Danshen root, such as Scutellaria barbata and Hedyotis diffusa in the treatment of cancer \[[@B8]--[@B20]\]. It should be mentioned that the current meta-analysis is the first systematic review of the application of Danshen formulae in cancer-assisted treatment. The current meta-analysis found that Danshen formulae can improve the clinical efficiency in cancer treatment. After the addition of Danshen formulae, RR and survival rates were significantly improved. However, it is not clear which components of Danshen formulae have anticancer effects during the treatment, and what role Danshen root plays, which should be the goal of further research.

4.3. Limitations {#sec4.3}
----------------

All literatures for this meta-analysis were from China, among which 4 were in English and the rest were in Chinese, and only one was multicenter study \[[@B10]\]. Blind methods have been described vaguely in many studies and most of the references were scored 4 points. Moreover, all types of researches were single-center studies with a small sample size and lack of data support for multicenter, large RCTs. The funnel plot analysis also found obvious asymmetry between the left and the right of funnel plot, therefore, the effect of Danshen formulae in assisting cancer treatment may be exaggerated. In addition to all of the above, the cycle of cancer treatment is extremely long and an army of patients died as their condition worsens during the treatment process, which leads to follow-up work is difficult, resulting in the inability to obtain valid data for many studies, and some literature related to this study cannot be included. Therefore, to better explore the contribution of Danshen formulae in cancer treatment, more large-scale and higher standard studies are needed.

4.4. Implications for Further Studies {#sec4.4}
-------------------------------------

Nearly 50% of the RCTs included in our study are related to lung cancer, indicating that Danshen formulae may be more widely used in lung cancer. Lung cancer is one of the most dangerous diseases, and it has a variety of treatment options, but the death rate is stubbornly high \[[@B2]\]. Except lung cancer, the included studies also cover leukemia, liver cancer, breast, colon cancer, and gastric cancer, and our study found that 9 kinds of herbs were used in combination with Danshen root in cancer treatment, suggesting that the pharmacological effects of these drugs together may be a mechanism to improve clinical efficacy and reduce side effects. Therefore, this study provides the basis for the clinical treatment and scientific research of Danshen for cancer. In terms of gender ratio, we found that men have a higher risk of cancer than women (605/440), suggesting that men should pour more attention into prevention of cancer, which was also a limitation of this paper, indicating that we should avoid gender selection bias by recruiting women to a certain extent in future studies. By inputting the dose form of Danshen formulae to statistical analysis, we found that there were 1 used granule preparation, 1 used tablet, and the other 11 used decoctions. Ling proved that TCM preparations more safer, effective, and easier to use than decoctions of traditional Chinese medicine \[[@B30]\], and the present study showed that the clinical curative effect and dosage forms of CHM were interconnected, interdependent, and mutually reinforcing with each other; drug application shall be familiar with drug characteristics on the premise of fully considering disease characteristics and age constitution and patient and choose the appropriate dosage forms, through the appropriate method to give full play to the effect, and make the drug in patients with optimal clinical curative effect \[[@B31], [@B32]\]. Therefore, rational selection of drug dosage forms is beneficial to enlighten and create new drugs, which can better promote the further development and research of new dosage forms with higher drug absorption rate. In terms of the treatment of cancer, in traditional western medicine, chemotherapy and radiotherapy are the main treatments for cancer. The purpose of these therapies is to kill or destroy cancer cells. Unfortunately, for most cancer treatments, it is difficult to distinguish between cancer cells and normal healthy cells, which leads to damage to normal cells \[[@B33], [@B34]\]. The results of this injury are known as complications and side effects of cancer treatment. There were 10 included studies showed that the formulae of Danshen had significant effect in reducing the side effect of vomiting and blood toxicity, which suggested that we could cooperate with the Danshen formulae in the treatment of cancer in the future to reduce the gastrointestinal reaction of patients. The results of subgroup analysis suggested that Danshen formulae might be taken advantage of for cancer treatment. At last, the exact pathologic and clinical pharmacological mechanisms of cancer are still largely unknown and should be studied further.

5. Conclusion {#sec5}
=============

Current findings suggested that Danshen formulae offered statistically significant benefits for cancer, which we generally considered safe. Thus, evidence from the existing study supported the use of Danshen formulae as a treatment for cancer. However, this study was based on several small‐sample studies. Therefore, studies with rigorous, large‐scale RCTs of Danshen formulae in treating of cancer were needed to further confirm its efficacy.
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###### 

Basic characteristics of the included studies.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Included trial         Publication language   Study design and investi-\   Type of cancer                       No.of participants (male/female;age years)   Intervention               Outcome index                                                                                                      Intergroup difference                                                                                                                                                                                                                                                                
                                                gational sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  ---------------------- ---------------------- ---------------------------- ------------------------------------ -------------------------------------------- -------------------------- ------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------- ------------------------------------------------
  Chen 2012 \[[@B8]\]    Chinese                RCT,Single cencer;China      Primary Liver Cancer                 38/11;44.7                                   41/8;47.1                  Danshen formulae                                                                                                   Vinorelbine +Cisplatin(NP)+Placebo (Huangqi, Huangjing, Jiaogulan, Lingzhi, Cangzhu, Nvzhenzi, Huanglian et al.)                                                                  1.RR; 2.Survival rate;3.Improvement of symptoms                                                    1,2.*P*\>0.05; 3\<0.05

  Gong 2018 \[[@B9]\]    English                RCT,Single cencer;China      Non-small cell lung cancer (NSCLC)   80/51;40-78                                  66/42;41-80                Vinorelbine +Cisplatin(NP)+Danshen formulae                                                                        Platinum-based therapy +Placebo (Jiegeng, Xingren, Yuxingcao, Ziwan, Kuandong, Zhebeimu, Banxia, Hexiancao, Shengdiyu, Huangqin, Dongguazi, Chenpi, Zhuru et al.)                 1.Survival Rates;2.MST                                                                             1,2.*P*\<0.05

  Guo 2017 \[[@B10]\]    English                RCT, Multi-cente;China       NSCLC                                20/9;38-77                                   28/4;38-77                 Platinum-based therapy +Danshen formulae                                                                           Radiotherapy                                                                                                                                                                      1.RR;2.Nausea; 3.Vomit;4.QOL; 5.Mildgastric/abdominal heaviness                                    1,2,3,5.*P*\<0.05;4.P\>0.05

  Lan 2003 \[[@B11]\]    English                RCT,Single cencer;China      Lung cancer                          16/10;70-77                                  13/8;70-79                 Radiotherapy+Danshen formulae                                                                                      DAP                                                                                                                                                                               RR(1.Short-term effect;2. Long-term effect)                                                        1*.P*\>0.052.*P*\<0.01

  Li 2017 \[[@B12]\]     Chinese                RCT,Single cencer;China      Leukemia                             10/15;(35.42±15.13                           13/12;37.97±13.45          DAP+Jiedu Huayu Fang                                                                                               Radiotherapy+placebo (Xuanshen,Yiyiren, Chenqianzi, Yinchen, Difuzi, Chuanwu, Ganjiang, Rougui, Wuzhuyu, Xiangfuzi, Chenpi, Shanzha, Laifuzi, Sanqi, Ruxiang, Yujin et al.)       1.RR(CR+PR);2.Leukopenia; 3.Platelet(PLT)decreased; 4.Hemoglobin(HGB)decreased                     1,3,4.*P*\<0.05;2.*P*\>0.05

  Mok 2007 \[[@B13]\]    English                RCT,Single cencer;China      Breast or colon cancer               5/50;32-75                                   6/50;39-72                 Radiotherapy+Danshen formulae                                                                                      Paclitaxel Injection+Cisplatin Injection                                                                                                                                          1.HGB decreas\                                                                                     1-4,*P*\>0.05;5,6.*P*\<0.05
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               -ed;2.Leukopenia;3.Neutropenia; 4.Thrombocytopenia;5.Nausea; 6.QOL                                 

  Shen 2017 \[[@B14]\]   Chinese                RCT,Single cencer;China      NSCLC                                22/21;57.2 ±7.3                              23/20;56.8±7.5             Paclitaxel Injection+Cisplatin Injection+Zilongjin tablet                                                          3-DCRT                                                                                                                                                                            1.RR;2.Leucopenia;3.Erythropenia; 4.Thrombocytopenia;5.Nausea;6.DCR                                1,2,3,5,6.*P*\<0.05;4.*P*\>0.05

  Wang 2010 \[[@B15]\]   Chinese                RCT,Single cencer;China      Primary liver cancer                 28/13;32-68                                  25/14;33-67                3-DCRT+Aixiao Aixiao Ruanganjian                                                                                   UFTM/FMV                                                                                                                                                                          1.RR;2.Leucopenia;3.Platelet descend; 4.Hemoglobin reduction.5.T-cells; 6.Survival rate;7.Nausea   1-7.P\<0.05

  Wen 1996 \[[@B16]\]    Chinese                RCT,Single cencer;China      Gastric cancer                       8/3;47-73                                    5/3;50-69                  UFTM/FMV+Jianpi Kangai mixtures                                                                                    DA/HA/IA                                                                                                                                                                          1.RR                                                                                               1.*P*\<0.05

  Xu 2004 \[[@B17]\]     Chinese                RCT,Single cencer;China      Acute myleoid leukemia               19/11;11-65                                  20/10;12-64                DA/HA/IA+Danshen formulae                                                                                          Radiotherapy+Placebo (TizisheN, huangbai, Baizhu, Gouqi, Huang jing, Tiandong, Maidong, Xuan shen, Nvzhenzi, Hanliancao, Pugonging, Banzhilian, Baihuasheshecao, Xiaoji et al.)   1.RR;2.Aminotransferase                                                                            1,2.*P*\<0.05

  Yan 1995 \[[@B18]\]    Chinese                RCT,Single cencer;China      Acute leukemia                       16/19;14-60                                  18/17;17-60                Radiotherapy+Danshen formulae                                                                                      General symptomatic treatment+Fufang Banmao Capsule                                                                                                                               1.RR;2.Survival rate                                                                               1.*P*\<0.05;2.*P*\<0.01

  Zeng 2015 \[[@B19]\]   Chinese                RCT,Single cencer;China      Liver cancer                         20/4;52.96±7.14                              19/5;53.95±10.25           General symptomatic treatment+Fuzhengkangai decoction                                                              DDP+VP-16                                                                                                                                                                         1.RR;2.ALT;3.AST;4.GGT;5.AFP;6.CR+PR; 7. CR+PR+NC; 8.Survival rates; 9.Nausea;10.Vomiting          1,4,7.*P*\<0.05; 2,3.P\<; 5,6,8,9,10.*P*\>0.05

  Zhang 2013\            Chinese                RCT,Single cencer;China      NSCLC                                Total:48/30;55±2.1                           DDP+VP-16d123+Xidan Tang   Vinorelbine +Cisplatin(NP)+Placebo (Huangqi, Huangjing, Jiaogulan, Lingzhi, Cangzhu, Nvzhenzi, Huanglian et al.)   1.Survival rate;2.Nausea, vomiting and loss of appetite                                                                                                                           1.*P*\<0.05; 2.*P*\>0.05                                                                           
  \[[@B20]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Types of cancer.

  -----------------------------------------------------------------------------
  Types of cancer          Included trial(s)   Sex(male/female);\   Frequency
                                               Total                
  ------------------------ ------------------- -------------------- -----------
  Lung cancer              Gong 2018           146/93               5

  Guo 2017                 48/13                                    

  Lan 2003                 29/18                                    

  Shen 2017                45/41                                    

  Zhang 2013               48/30                                    

                           Total:316/195                            

  Leukemia                 Li 2017             23/27                3

  Xu 2004                  39/21                                    

  Yan 1995                 34/36                                    

                           Total:96/84                              

  Liver cancer             Chen 2012           79/19                3

  Wang 2010                53/27                                    

  Zeng 2015                39/9                                     

                           Total:171/55                             

  Gastric cancer           Wen 1996            11/6                 1

                           Total:11/6                               

  Breast or colon cancer   Mok 2007            11/100               1

                           Total:11/100                             
  -----------------------------------------------------------------------------

###### 

The constituent of Danshen formulae in each included study.

  Included trials                      Chuanxiong formula             Ingredient                                                                  
  ------------------------------------ ------------------------------ ------------------------------ ----------------------------- -------------- -----------------
  Chen 2012                            Gexiazhuyu decotion            Radix salviae miltiorrhizae    Danshen root                  Danshen        9
  Astragalus mongholicus               Milkvetch Root                 Huangqi                        14                                           
  Semen persicae                       Peach seed                     Taoren                         9                                            
  Flos carthami                        Safflowe                       Honghua                        6                                            
  Paeoni                               paeonol                        Danpi                          12                                           
  Rhizoma cyperi                       Nutgrass galingale rhizome     Xiangfu                        10                                           
  Fructus citri aurantii immaturus     Immature bitter orange         Zhiqiao                        12                                           
  Agkistrodon seu bungarus             Hedyotis diffusa               Baihuasheshecao                16                                           
  Radix scrophulariae ningpoensis      Radix scrophulariae            Xuanshen                       14                                           
                                                                                                                                                  
  Gong 2018                            Jupi Zhuru decoction           Radix salviae miltiorrhizae    Danshen root                  Danshen        15
  Pericarpium citri reticulatae        Dried Tangerine                Chenpi                         9                                            
  Pinellia ternata                     Rhizoma pinelliae              Jiangbanxia                    9                                            
  Bambusa turdoides munro              Bamboo shavings                Jiangzhuru                     9                                            
  Zizyphus jujuba                      Chinese date                   Dazao                          9                                            
  Glycyrrhiza uralensis                Liquorice root                 Gancao                         6                                            
                                                                                                                                                  
  Guo 2017                             TCM formulae decoction         Astragalus mongholicus         Milkvetch Root                Huangqi        30
  Rhizoma atractylodis macrocephalae   Largehead atractylodes         Baizhu                         9                                            
  Poria                                Poria cocos                    Fuling                         15                                           
  Radix glehniae                       Coastal glehnia root           Beishashen                     30                                           
  Radix adenophorae                    Fourleaf ladybell root         Nanshashen                     30                                           
  Radix asparagi                       Cochinchinese asparagus root   Tiandong                       15                                           
  Radix ophiopogonIs                   Dwarf lilyturf tuber           Maidong                        15                                           
  Radix salviae miltiorrhizae          Danshen root                   Danshen                        30                                           
  Selaginella doederleinii hicr        Selaginella doederleinii       Shishangbai                    30                                           
                                                                                                                                                  
  Lan 2003                             TCM formulae decoction         Adenophora stricta             Radix Adenophorae             Shashen        30
  Bulbus fritillariae cirrhosae        Tendrilleaf fritillary bulb    Chuanbeimu                     10                                           
  Astragalus mongholicus bunge         Milkvetch root                 Huangqi                        30                                           
  Ophiopogon japonicus                 Dwarf lilyturf tuber           Maidong                        15                                           
  Fallopia multiflora                  Tuber fleeceflower root        Heshouwu                       30                                           
  Rehmannia glutinosa                  Prepared rehmannia root        Shudihuang                     10                                           
  Dioscorea opposita                   Common Yam Rhizome             Shanyao                        30                                           
  Alismatis Rhizoma                    Alisma orientale               Zexie                          15                                           
  Fructus Corni                        Cornus officinalis             Shanzhuyu                      10                                           
  Glycyrrhiza uralensis                Liquorice root                 Gancao                         10                                           
  Rhizoma Phragmitis                   Reed rhizome                   Lugen                          30                                           
  Lonicera japonica Thunb              Lonicera japonica              Jinyinhua                      15                                           
  Morus alba L.                        White mulberry root-bark       Sangbaipi                      15                                           
  Radix Sophorae Tonkinensis           Radix sophorae tonkinensis     Shandougen                     15                                           
  Gypsum fibrosum                      Gypsum fibrosum                Shengshigao                    30                                           
  Scutellariae baicalensis             Radix scutellariae             Huangqin                       15                                           
  Codonopsis pilosula                  Danshen root                   Danshen                        30                                           
  Radix et rhizoma rhei                Rhubar                         Dahuang                        15                                           
                                                                                                                                                  
  Li 2017                              Jiedu Huayu Fang               Lygodium japonicum             Indigo Naturals               Qingdai        Not mentioned
  Paris polyphylla Smith               Flea                           Zaoxiu                                                                      
  Fructus Psoraleae                    Psoraleae                      Buguzhi                                                                     
  Rhizoma Polygoni Cuspidati           Polygonum cuspidatum           Huzhang                                                                     
  Radix salviae miltiorrhizae          Danshen root                   Danshen                                                                     
  Atractylodes macrocephala Koidz      Largehead atractylodes rhizo   Baizhu                                                                      
  Asarum sagittarioides                Cremastra appendiculata        Shancigu                                                                    
  Rhizoma Ligustici Chuanxiong         Sichuan lovage rhizome         Chuanxiong                                                                  
                                                                                                                                                  
  Mok 2007                             TCM formulae granules          Curcuma zedoaria               Rhizoma curcumae              Ezhu           Not mentioned
  Sparganium simplex Huds              Rhizoma spargani               Sanleng                                                                     
  Radix salviae miltiorrhizae          Danshen root                   Danshen                                                                     
  Leonurus artemisia                   Herba leonuri                  Yimucao                                                                     
  Radix scrophulariae                  Scrophularia ningpoensis       Xuanshen                                                                    
  Polyporus                            Polyporus umbellatus           Zhuling                                                                     
  Coix lacrymajobi                     Coix seed                      Yiyiren                                                                     
  Semen Plantaginis                    Plantain seed                  Cheqianzi                                                                   
  Herba lysimachiae                    Longhairy antenoron Herb       Jinqiancao                                                                  
  Spora lygodii                        Lygodium japonicum             Haijinsha                                                                   
                                                                                                                                                  
  Shen 2017                            Zilongjin Tablet               Astragalus mongholicus         Milkvetch root                Huangqi        0.65g per piece
  Radix angelicae hinensis             Chinese angelica               Danggui                                                                     
  Solanum lyratum thunb                Solanum lyratum thunb          Baiying                                                                     
  Solanum nigrum                       Nightshade                     Longkui                                                                     
  Radixsalviae miltiorrhizae           Danshen root                   Danshen                                                                     
  Portulaca grandiflora hook           Scutellariae barbatae          Banzhilian                                                                  
  Duchesnea indica                     Duchesnea                      Shemei                                                                      
  Turmeric Curcumae                    Turmeric                       Yujin                                                                       
                                                                                                                                                  
  Wang 2010                            Aixiao Ruanganjian             Panax ginseng                  Ginseng                       Renshen        Not mentioned
  Curcuma zedoaria                     Rhizoma Curcumae               Ezhu                                                                        
  Radix salviae miltiorrhizae          Danshen root                   Danshen                                                                     
  Semen coicis                         Coix seed                      Yiyiren                                                                     
  Spreading hedyotis herb              Hedyotis diffusa               Baihuasheshecao                                                             
  Portulaca grandiflora hook           Scutellariae barbatae          Banzhilian                                                                  
  Bletilla striata                     Bletilla                       Baiji                                                                       
  Rehmannia glutinosa                  Smilax glabra                  Tufuling                                                                    
  Semen persicae                       Peach seed                     Taoren                                                                      
  Rafetus swinhoei                     Cantharides                    Banao                                                                       
  Lycium dasystemum Pojark             Babury wolfberry fruit         Gouqizi                                                                     
  Trionyx sinensis                     Trionycis carapax              Biejia                                                                      
  Rhizoma paridis                      Flea                           Zaoxiu                                                                      
  Radix sophorae flavescentis          Lightyellow sophora root       Kushen                                                                      
                                                                                                                                                  
  Wen 1996                             Jianpi Kangai decoction        Pseudostellaria heterophylla   Radix pseudostellariae        Taizishen      12
  Atractylodes macrocephala koidz      Roasted rhizoma atractylois    Chaobaizhu                     12                                           
  Poria                                Poria cocos                    Fuling                         12                                           
  Rhizoma pinelliae ternatae           Pinellia tuber                 Banxia                         12                                           
  ericarpium citri reticulatae         Tangerine Peel                 Chenpi                         12                                           
  Radix salviae miltiorrhizae          Danshen root                   Danshen                        20                                           
  Sargentodoxa cuneata.                 Sargent gloryvine             Hongteng                       20                                           
  Smilax china L                       Smilax china                   Baqia                          30                                           
  Concha ostreae                       Oysters                        Shengmuli                      30                                           
  Prunella vulgaris                    Self heal                      Xiakucao                       30                                           
                                                                                                                                                  
  Xu 2004                              TCM formulae decoction         Radix astragali seu            Milkvetch Root                Shenghuangqi   Not mentioned
  Rehmannia glutinosa Libosch          Radix rehmanniae               Shengdihuang                                                                
  Pseudostellaria heterophylla         Radix pseudostellariae         Taizishen                                                                   
  Dioscorea nipponicaMakino            Ningpo yam rhizome             Chuanshanlong                                                               
  Radix salviae miltiorrhizae          Danshen root                   Danshen                                                                     
  Leonurus artemisia                   Radix salviae miltiorrhizae    Yimucao                                                                     
  Periostracum cicadae                 Cicada Slough                  Chantui                                                                     
  Achyranthes bidentata blume          Achyranthes longifolia         Huainiuxi                                                                   
                                                                                                                                                  
  Yan 1995                             TCM formulae decoction         Astragalus mongholicus         Milkvetch root                Huangqi        15
  Codonopsis pilosula                  Codonopsis                     Dangshen                       15                                           
  Atractylodes macrocephala Koidz      Largehead atractylodes rhizo   Baizhu                         15                                           
  Poria                                Poria cocos                    Fuling                         12                                           
  Radix Angelicae Sinensis             Chinese angelica               Danggui                        15                                           
  Colla corii Asini                    colla corii asini              Ajiao                          15                                           
  Lycium dasystemum Pojark             Babury Wolfberry Fruit         Gouqizi                        15                                           
  Fructus psoraleae                    Psoraleae                      Buguzhi                        15                                           
  Fallopia multiflora                  Tuber fleeceflower root        Heshouwu                       15                                           
  Spreading hedyotis Herb              Hedyotis diffusa               Baihuasheshecao                20                                           
  Herba cirsii setosi                  Common cephalanoplos herb      Xiaoji                         15                                           
  Radix salviae miltiorrhizae          Danshen root                   Danshen                        15                                           
  Millettia dielsiana                  Caulis spatholobi              Jixueteng                      15                                           
  Sparganium simplex Huds              Rhizoma spargani               Sanleng                        15                                           
  Curcuma zedoaria                     Rhizoma curcumae               Ezhu                           15                                           
                                                                                                                                                  
  Zeng 2015                            Fuzhengkangai decoction        Cynanchum paniculatum          Paniculate swallowwort root   Xuchangqing    20
  Atractylodes macrocephala            Largehead atractylodes rhizo   Shengbaizhu                    15                                           
  Turmeric Curcumae                    Turmeric                       Yujin                          12                                           
  Radix salviae miltiorrhizae          Danshen root                   Danshen                        30                                           
  ArtemisiacapillarisThunb             Virgate wormwood herb          Yinchen                        30                                           
  Fructus citri aurantii immatur       Immature bitter orange         Chaozhishi                     15                                           
  Portulaca grandiflora hook           Scutellariae barbatae          Banzhilian                     30                                           
  Solanum lyratum thunb                Solanum lyratum thunb          Baiying                        20                                           
  Astragalus mongholicus               Milkvetch root                 Shenghuangqi                   40                                           
  Cleistocactus sepium                 Cuttlebone                     Wuzeigu                        20                                           
  Curcuma zedoaria                     Rhizoma curcumae               Ezhu                           10                                           
  Rhizoma Coptidis                     Coptis root                    Huanglian                      6                                            
  Trichosanthes kirilowii Maxim        Pericarpium trichosanthis      Gualoupi                       15                                           
                                                                                                                                                  
  Zhang 2013                           Xidan Tang                     Astragalus mongholicus         Milkvetch root                Huangqi        30
  Bletilla striata                     Bletilla                       Baiji                          12                                           
  Poria                                Poria cocos                    Fuling                         15                                           
  Ganoderma Lucidum Karst              Lucid ganoderma                Lingzhi                        15                                           
  Radix salviae miltiorrhizae          Danshen root                   Danshen                        10                                           
  Rhizoma Ligustici Chuanxiong         Sichuan lovage rhizom          Chuanxiong                     9                                            
  Euchresta japonica Hook              Vietnamese sophora root        Shandougen                     6                                            
  Fructus Camptothecae Acuminatae      Common Camptotheca Fruit       Xishuguo                       10                                           
  Glycyrrhiza uralensis                Liquorice root                 Gancao                         5                                            

###### 

The top 9 frequency Chinese herb medicines of formulae.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------
  Latin\                               English\                             Chinese name      Frequentcy\   The total frequency (%)\   Cumulative percentiles (%)
  name                                 name                                                                                            
  ------------------------------------ ------------------------------------ ----------------- ------------- -------------------------- ----------------------------
  Radix salviae miltiorrhizae          Danshen root                         Danshen           13            100                        17.11

  Astragalus mongholicus bunge         Milkvetch root                       Huangqi           8             61.54                      10.53

  Rhizoma atractylodis macrocephalae   Largehead atractylodes Poria cocos   Baizhu            5             38.46                      6.76

  Curcuma zedoaria                     Rhizoma curcumae                     Ezhu              4             30.77                      5.26

  Poria                                Coastal glehnia root                 Fuling            4             30.77                      5.26

  Agkistrodon seu bungarus             Hedyotis diffusa                     Baihuasheshecao   3             23.08                      3.95

  Adenophora stricta                   Radix Adenophorae                    Shashen           3             23.08                      3.95

  Glycyrrhiza uralensis                Liquorice root                       Gancao            3             23.08                      3.95

  Portulaca grandiflora hook           Scutellariae barbatae                Banzhilian        3             23.08                      3.95
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Risk of bias assessments for included studies.

  Included studies   A    B    C    D    E    F    G    Total
  ------------------ ---- ---- ---- ---- ---- ---- ---- -------
  Chen 2012          \+   ?    \+   \+   \+   ?    \+   4
  Gong 2018          \+   ?    \+   \+   \+   ?    \+   5
  Guo 2017           \+   ?    ?    \+   \+   \+   \+   5
  Lan 2003           \+   \-   \+   \-   \+   ?    \+   4
  Li 2017            \+   \-   \-   ?    \+   \+   \+   4
  Mok 2007           \+   ?    \+   \+   \+   \+   \+   5
  Shen 2017          \+   ?    \-   ?    \+   ?    \+   4
  Wang 2010          \+   \-   \-   ?    \+   \+   \+   4
  Wen 1996           \+   ?    ?    \-   \+   \+   \+   4
  Xu 2004            \+   ?    ?    \+   \+   \-   \+   4
  Yan 1995           \+   \-   ?    \+   \+   \-   \+   4
  Zeng 2015          \+   \-   ?    ?    \+   \+   \+   4
  Zhang 2013         \+   ?    \-   ?    \+   \+   \+   4

A, random sequence generation (selection bias); B, allocation concealment (selection bias).

C, blinding of participants and personnel (performance bias); D, blinding of outcome assessment(detection bias).

E, incomplete outcome data (attrition bias); F, selective reporting (reporting bias); G, other bias. +, low risk of bias;--, high risk of bias; ?, unclear risk of bias.

[^1]: Guest Editor: Hwan-suck Chung
